Ultragenyx Pharmaceutical (NASDAQ:RARE) : Wednesdays money flow indicated an uptick to downtick ratio was at 1.28. The total value of inflow transactions on upticks was $15.2 million, whereas, the total value of outflow trades on downticks was $11.85 million. The total money flow was $3.35 million, which shows a mild bullish bias. The total money flow into the stock in block trades was $2.13 million. The total value of the trades done on upticks was $2.13 million. Ultragenyx Pharmaceutical (NASDAQ:RARE) was trading with a -1.93% change over previous days close. It fell $0.98 during the day and reached $49.75. The stock was 1.18% compared to the previous weeks close.
In an insider trading activity, Agarwal Sunil, (Chief Medical Officer) of Ultragenyx Pharmaceutical Inc., unloaded 650 shares at an average price of $54.16 on June 20, 2016. The total amount of the transaction was worth $35,204, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing. Currently the company Insiders own 10.1% of Ultragenyx Pharmaceutical shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -6.82% . Institutional Investors own 95.02% of Ultragenyx Pharmaceutical shares. During last six month period, the net percent change held by insiders has seen a change of -7.4%.
The company shares have dropped -51.16% from its 1 Year high price. On Jul 20, 2015, the shares registered one year high at $137.05 and the one year low was seen on Jun 27, 2016. The 50-Day Moving Average price is $62.09 and the 200 Day Moving Average price is recorded at $69.71. Ultragenyx Pharmaceutical (NASDAQ:RARE): The stock opened at $52.16 on Wednesday but the bulls could not build on the opening and the stock topped out at $52.18 for the day. The stock traded down to $48.88 during the day, due to lack of any buying support eventually closed down at $49.75 with a loss of -1.93% for the day. The stock had closed at $50.73 on the previous day. The total traded volume was 887,249 shares.
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Its pipeline consists of two product categories: biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies. Its products are KRN23 (UX023), rhGUS (UX003), rhPPCA (UX004), Triheptanoin (UX007) and SA-ER (UX001). KRN23 is a fully human monoclonal antibody administered via subcutaneous injection. rhGUS is an intravenous (IV), enzyme replacement therapy for the treatment of mucopolysaccharidosis 7. rhPPCA is an enzyme replacement therapy for galactosialidosis. Triheptanoin is a medium odd-chain triglyceride of seven-carbon fatty acids. SA-ER is for the treatment of hereditary inclusion body myopathy (HIBM).